ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,463.54
0.08%
US Tech 100
18,493.20
-0.14%
Dow Jones
40,539.93
-0.12%
Brent Oil
78.655
-0.62%
Bitcoin
66,515.42
-0.46%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lisata Therapeutics Inc (LSTA)

  7. Lisata Therapeutics Inc (LSTA) News

LSTA

Lisata Therapeutics (LSTA)

Lisata Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LSTA
DateTimeSourceHeadlineSymbolCompany
07/18/20248:00AMGlobeNewswire Inc.Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapyNASDAQ:LSTALisata Therapeutics Inc
07/16/20248:00AMGlobeNewswire Inc.Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line CholangiocarcinomaNASDAQ:LSTALisata Therapeutics Inc
07/10/20248:00AMGlobeNewswire Inc.Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical ModelNASDAQ:LSTALisata Therapeutics Inc
06/13/20248:30AMGlobeNewswire Inc.Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX TrialNASDAQ:LSTALisata Therapeutics Inc
05/28/20248:30AMGlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
05/20/20248:30AMGlobeNewswire Inc.Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic CancerNASDAQ:LSTALisata Therapeutics Inc
05/10/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LSTALisata Therapeutics Inc
05/09/20244:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LSTALisata Therapeutics Inc
05/09/20244:05PMGlobeNewswire Inc.Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
05/08/20248:00AMGlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
05/02/20248:00AMGlobeNewswire Inc.Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024NASDAQ:LSTALisata Therapeutics Inc
04/23/20247:30AMGlobeNewswire Inc.Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
04/09/20248:30AMGlobeNewswire Inc.Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of OsteosarcomaNASDAQ:LSTALisata Therapeutics Inc
04/03/20248:30AMGlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
03/21/20248:00AMGlobeNewswire Inc.Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of OsteosarcomaNASDAQ:LSTALisata Therapeutics Inc
03/04/20248:00AMGlobeNewswire Inc.Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰNASDAQ:LSTALisata Therapeutics Inc
02/29/20244:05PMGlobeNewswire Inc.Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
02/22/20248:00AMGlobeNewswire Inc.Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern TimeNASDAQ:LSTALisata Therapeutics Inc
02/20/20248:00AMGlobeNewswire Inc.Lisata Therapeutics to Present at BIO CEO & Investor ConferenceNASDAQ:LSTALisata Therapeutics Inc
01/18/20248:30AMGlobeNewswire Inc.Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto RicoNASDAQ:LSTALisata Therapeutics Inc
01/17/20248:00AMGlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma MultiformeNASDAQ:LSTALisata Therapeutics Inc
01/04/20248:00AMGlobeNewswire Inc.Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care TherapyNASDAQ:LSTALisata Therapeutics Inc
12/12/20238:00AMGlobeNewswire Inc.Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
11/28/20234:05PMGlobeNewswire Inc.Lisata Therapeutics to Present at NobleCon19 Investor ConferenceNASDAQ:LSTALisata Therapeutics Inc
11/09/20234:05PMGlobeNewswire Inc.Lisata Therapeutics Announces Participation in Upcoming Conferences in NovemberNASDAQ:LSTALisata Therapeutics Inc
11/02/20234:05PMGlobeNewswire Inc.Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
10/26/20238:00AMGlobeNewswire Inc.Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern TimeNASDAQ:LSTALisata Therapeutics Inc
10/24/20238:00AMGlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating PeptideNASDAQ:LSTALisata Therapeutics Inc
10/17/20238:00AMGlobeNewswire Inc.Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer NASDAQ:LSTALisata Therapeutics Inc
09/28/20238:00AMGlobeNewswire Inc.Lisata Therapeutics Announces Participation in Upcoming Conferences in OctoberNASDAQ:LSTALisata Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LSTA

Your Recent History

USOTC
CNNA
Cann American (CE)
USOTC
SAPX
Seven Arts Entertainment (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
RDGL
Vivos (QB)
USOTC
CEOS
CeCors (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
HHSE
Hannover House (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
CLNV
Clean Vision (QB)
USOTC
RNVA
Rennova Health (CE)
USOTC
GDVM
Global Developments (PK)
NASDAQ
RNAZ
TransCode Therapeutics
COIN
BTCUSD
Bitcoin
NASDAQ
TSLA
Tesla
USOTC
BLLB
Bell Buckle (PK)
USOTC
IJJP
IJJ (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved